Monopar Therapeutics MNPR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$3.89M-48.3% | -$5.2M+52.4% | -$3.44M-164% | -$2.45M-43.0% | -$2.62M-59.9% | ||
| $1.69M+24.9% | $1.1M+296% | $1.1M+452% | $1.28M+283% | $1.36M+312% | ||
| -$3.47M+38.7% | -$3.37M-68.6% | -$2.09M-94.7% | -$1.08M+35.7% | -$5.66M-242% | ||
| -$5.58M-1,614% | -$62.19M-334% | -$2.13M-316% | $1.19M+49,101% | -$325.83K+66.9% | ||
| -$200.2K-73.1% | $0-100% | $92.39M— | -$316.85K— | -$115.68K-104% | ||
| -$9.29M-52.2% | —— | $88.18M+88,411% | -$209.47K+87.6% | -$6.1M-1,227% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monopar Therapeutics generate?
- Monopar Therapeutics (MNPR) generated -$10.0M in operating cash flow over the trailing twelve months.
- Where does Monopar Therapeutics's cash flow data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.